Latest Conference Articles

July 4th 2015, 5:36am

ESMO Gastrointestinal Cancers Congress

Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).

July 3rd 2015, 3:09pm

ESMO Gastrointestinal Cancers Congress

Findings from a large expanded access program have confirmed the efficacy and safety of regorafenib in patients with previously treated metastatic colorectal cancer.

July 3rd 2015, 12:11pm

ESMO Gastrointestinal Cancers Congress

TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.

July 3rd 2015, 11:28am

ESMO Gastrointestinal Cancers Congress

Adding an NK1 antagonist to a 5-HT3 receptor antagonist with dexamethasone improved antiemetic control for patients with colorectal cancer treated with an oxaliplatin-based regimen compared with the 5-HT3 antagonist and dexamethasone alone.

July 3rd 2015, 9:11am

ESMO Gastrointestinal Cancers Congress

Andrew Zhu, MD, PhD, Associate Professor, Medicine, Harvard Medical School Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the REACH study, which looks at ramucirumab in advanced hepatocellular carcinoma.

July 3rd 2015, 8:57am

ESMO Gastrointestinal Cancers Congress

Josep Tabernero, MD, PhD, summarized novel agents that are currently under exploration for patients with gastric cancer.

July 3rd 2015, 6:18am

ESMO Gastrointestinal Cancers Congress

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the safety profile of the phase III B CONSIGN study, which looked at regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).

July 2nd 2015, 12:25pm

ESMO Gastrointestinal Cancers Congress

Novel agents that target the replication of the hepatitis C virus are poised to have a far-reaching impact on the prevention and recurrence of hepatocellular carcinoma and have shown the ability to reverse liver fibrosis, including cirrhosis in patients with end-stage HCC.

July 2nd 2015, 10:52am

ESMO Gastrointestinal Cancers Congress

Investigators reported a clinically meaningful extension of overall survival with IMM-101 plus gemcitabine in patients with metastatic pancreatic cancer.

July 2nd 2015, 8:56am

ESMO Gastrointestinal Cancers Congress

Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the phase III Sirflox study, which looked at selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres for the treatment of metastatic colorectal cancer.

July 2nd 2015, 7:48am

ESMO Gastrointestinal Cancers Congress

Philip Philip MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, discusses the use of the investigational drug evofosfamide for pancreatic cancer.

July 1st 2015, 1:49pm

ESMO Gastrointestinal Cancers Congress

Andrew Hendifar, MD, MPH, Assistant Professor of Medicine at Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses the use of a PEGylated form of rHuPH20 (PEGPH20) added to nab-paclitaxel/gemcitabine for pancreatic cancer patients with high levels of hyaluronan (HA).

July 1st 2015, 1:34pm

ESMO Gastrointestinal Cancers Congress

Results from a pooled dataset of more than 6000 patients with metastatic colorectal cancer found an association between low body mass index and a worse median overall survival with first-line bevacizumab and chemotherapy, suggesting that low BMI could be a prognostic factor for worse outcomes.

July 1st 2015, 8:48am

ESMO Gastrointestinal Cancers Congress

S. Yousuf Zafar, MD, Associate Professor of Medicine at Duke Cancer Institute, discusses the potential link between low body mass index (BMI) and survival outcomes in metastatic colorectal cancer.

June 20th 2015, 10:55am

International Conference on Malignant Lymphoma

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

June 20th 2015, 10:22am

International Conference on Malignant Lymphoma

Infusions of CTL019 achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive non-Hodgkin lymphoma.

June 20th 2015, 8:52am

International Conference on Malignant Lymphoma

A three-drug combination comprising the novel Bcl-2 inhibitor venetoclax, bortezomib, and dexamethasone demonstrated a clinical benefit in heavily pretreated patients with relapsed/refractory multiple myeloma.

June 20th 2015, 8:08am

International Conference on Malignant Lymphoma

Lenalidomide in combination with rituximab and as maintenance monotherapy is highly active in patients with relapsed/refractory central nervous system non-Hodgkin lymphoma.

June 20th 2015, 6:00am

International Conference on Malignant Lymphoma

Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

June 19th 2015, 3:32pm

International Conference on Malignant Lymphoma

Adrian Wiestner, MD, PhD, National Institutes of Health, National Heart, Lung, and Blood Services, discusses findings from the phase III HELIOS trial, which explored the addition of ibrutinib to bendamustine and rituximab for patients with relapsed/refractory chronic lymphocytic leukemia.